###begin article-title 0
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 31 46 31 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 61 76 61 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Single nucleotide polymorphisms (SNPs) in the tightly linked LOC387715/ARMS2 and HTRA1 genes have been associated with age-related macular degeneration (AMD). We tested whether these SNPs are associated with AMD in Israeli populations, if they underlie variable phenotype and response to therapy in neovascular AMD (NVAMD), and if HTRA1 expression in vivo is associated with its promoter variant.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 27 42 27 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 381 386 381 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 494 506 <span type="species:ncbi:9606">participants</span>
Genotyping for the  SNP in LOC387715/ARMS2 and the  SNP in HTRA1 was performed on 255 NVAMD patients and 119 unaffected controls from Ashkenazi and Sephardic Jewish, and from Arab origins which are the main ethnic groups composing the Israeli population. Genotyping was correlated with phenotype and response to therapy among 143 patients who underwent photodynamic therapy (PDT). HTRA1 mRNA levels in white blood cells (WBCs), measured by quantitative PCR, were correlated with genotype in 27 participants.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Both SNPs were in almost complete linkage disequilibrium (D'=0.96-1). Homozygotes for the T allele of  had an odds ratio (OR) of 8.6, with a 95% confidence interval (CI) of 3.5-20.8, and homozygotes for the A allele of  had an OR of 10.7, with a 95% CI of 3.2-35.7, for having AMD (p<0.00001). There was no association among these SNPs and phenotype or response to PDT. HTRA1 mRNA levels in WBCs were not associated with  genotypes.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 12 27 12 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
The  SNP in LOC387715/ARMS2 and the  SNP in HTRA1 are strongly associated with NVAMD in this Israeli population. These variants do not have a major contribution to the variable phenotype and response to PDT which characterize NVAMD.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 319 334 319 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 535 536 535 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
Single nucleotide polymorphisms (SNPs) in chromosome 10q26 are associated with the risk for having age-related macular degeneration (AMD) in several populations [1-18]. Since several 10q26 SNPs are associated with disease risk, it has been difficult to determine if the T allele of  located in the coding region of the LOC387715/ARMS2 (age-related maculopathy susceptibility 2) gene, or the A allele of  located in the promoter region of high-temperature requirement factor A1 (HTRA1) have a role in the pathogenesis of the disease [6-9,13,19].
###end p 11
###begin p 12
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 156 157 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 158 160 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 242 247 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 267 268 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 269 270 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
The HTRA1 gene encodes a heat shock serine protease which is expressed in the retina and can regulate transforming growth factor-beta (TGF-beta) signaling [7,20]. Evidence has conflicted with respect to the correlation between  genotypes and HTRA1 expression levels [6-8].
###end p 12
###begin p 13
###xml 4 19 4 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 96 111 96 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 359 374 359 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
The LOC387715/ARMS2 gene encodes a putative 12 kDa protein. Although it has been suggested that LOC387715/ARMS2 may not actually encode a protein, recent data has shown that it encodes a mitochondrial outer membrane protein that is also expressed in the retina [6]. The T allele of  changes amino acid 69 from alanine to serine (A69S variant) in the putative LOC387715/ARMS2 protein [6,13]. Fritsche [21] and colleagues recently described a related variant in this gene that is associated with AMD and results in rapid mRNA turnover and undetectable expression levels in homozygous carriers.
###end p 13
###begin p 14
###xml 597 600 597 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 856 861 856 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 916 918 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 1009 1011 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 532 539 <span type="species:ncbi:9606">patient</span>
Neovascular AMD (NVAMD) shows variable phenotype in terms of several parameters, including age of onset, neovascular lesion type and size, and response to treatment. Efforts are underway to identify genetic and other biomarkers that correlate with these various disease parameters. Of particular interest would be the identification of pharmacogenetic markers that might be able to predict response to therapy, since such information could potentially be used to guide choice, and perhaps frequency, of treatment for the individual patient. Recently, a genetic variant in the complement factor H (CFH) gene, which is strongly associated with AMD, has been reported to be associated with neovascular lesion type, size, and response to photodynamic therapy (PDT) and injections of the antivascular endothelial growth factor compound bevacizumab [22-26]. The HTRA1 polymorphism was associated with classic lesion type [26]. However, similar associations have not been consistently found in other populations [10,27,28].
###end p 14
###begin p 15
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 171 186 171 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 693 698 693 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 803 808 803 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 595 603 <span type="species:ncbi:9606">patients</span>
###xml 876 884 <span type="species:ncbi:9606">patients</span>
To test the association of the 10q26 SNPs with NVAMD in Israeli populations and to expand our knowledge about phenotype-genotype correlation, we first evaluated HTRA1 and LOC387715/ARMS2 polymorphisms and NVAMD risk in Israel. The study included Arabs, Sephardic Jews, and Ashkenazi Jews which are the main ethnic groups composing the Israeli population. After finding a significant association, similar in magnitude to that reported in other populations, we assessed if these SNPs could account for some of the observed variation in clinical characteristics and response to PDT among the NVAMD patients. Finally, as another approach to explore whether the SNP in the 5'-upsteam region of the HTRA1 promoter influences promoter activity, we tested to see if there was a correlation between genotype and HTRA1 mRNA levels in vivo as measured in the white blood cells (WBCs) of patients and controls.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and genotyping
###end title 17
###begin p 18
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 906 909 906 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 1142 1143 1138 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 417 424 <span type="species:ncbi:9606">patient</span>
###xml 1003 1011 <span type="species:ncbi:9606">patients</span>
###xml 1091 1099 <span type="species:ncbi:9606">patients</span>
###xml 1177 1185 <span type="species:ncbi:9606">patients</span>
The study included 255 NVAMD patients recruited from four retina clinics in Israel and 119 unaffected controls (from the department of Ophthalmology) who were evaluated for routine eye examination or for pathologies other than AMD, in the Department of Ophthalmology of the Hadassah - Hebrew University Medical Center in Jerusalem, Israel. Institutional Ethics Committee approval was obtained for the study, and each patient signed an informed consent form. AMD was diagnosed and graded according to the age related eye disease study (AREDS) trial classification [29]. Inclusion criteria for the control group included age over 60 years, clear cornea, lens, and vitreous which enabled ophthalmoscopy, and absence of intermediate size drusen, multiple small drusen, or retinal pigment epithelial abnormalities characteristics of AMD (AREDS category I). The data set was described in a manuscript evaluating CFH variants in the Israeli population [30]. Briefly, female:male ratio was balanced between AMD patients and controls. Mean age in the controls (70.8+/-8.2) was lower than that of AMD patients (78.1+/-7.6; p<0.05, unpaired, two-sided, t-test). Median follow-up of NVAMD patients having PDT was 16 months (range 1-156 months).
###end p 18
###begin p 19
###xml 102 110 <span type="species:ncbi:9606">patients</span>
WBCs were separated from blood samples from 27 individuals included in the genotyping study (22 NVAMD patients and 5 unaffected controls). These samples were used for RNA extraction. For WBC separation, 4 CC of whole blood were drawn and shipped to the laboratory on wet ice. RNA was then extracted as described below.
###end p 19
###begin p 20
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 551 552 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
The Israeli population is composed of several ethnic groups, which include Ashkenazi Jews, Sephardic Jews, and Arabs. Studies showed that these subpopulations may be genetically defined, for example, by polymorphisms and microsatellite loci on the Y chromosome [31]. Intermarriage between the groups was uncommon among parents of the elderly individuals included in the study. The control group included 10 Arabs, 40 Sephardic Jews, and 68 Ashkenazi Jews, while the study group included 11 Arabs, 75 Sephardic Jews, and 163 Ashkenazi Jews (p=0.13, chi2 test). The ethnicity of one individual from the control group and 6 NVAMD patients was unknown.
###end p 20
###begin p 21
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 110 125 110 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 210 217 210 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
Genotyping for the  SNP in the putative promoter region of HTRA1 and for the  SNP in the coding region of the LOC387715/ARMS2 gene was performed. This was done by sequencing PCR products containing these SNPs (Table 1).
###end p 21
###begin title 22
Primers used for genotyping and QPCR.
###end title 22
###begin p 23
###xml 54 69 54 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
Sequence of primers which were used for genotyping of LOC387715/ARMS2 () and HTRA1 () SNPs and for QPCR for assessment of HTRA1 mRNA levels.
###end p 23
###begin p 24
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 1331 1333 1331 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 1369 1370 1369 1370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1555 1556 1555 1556 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1602 1603 1602 1603 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 823 831 <span type="species:ncbi:9606">patients</span>
###xml 1238 1246 <span type="species:ncbi:9606">patients</span>
###xml 1345 1353 <span type="species:ncbi:9606">patients</span>
Detailed retrospective clinical information was available on a subgroup of 143 sequential NVAMD patients (of the 255 patients enrolled in the study) who were treated with PDT at the Hadassah-Hebrew University Medical Center. These patients were included in the phenotype-genotype analysis and for the purpose of analysis eyes of these patients which underwent PDT were considered as the study eye. Fluorescein angiograms were reviewed by retina specialists (I.C., E.B., I.H., and E.A.) who were masked with respect to genotype results; choroidal neovascularization was classified as classic, predominantly classic, minimally classic, or occult following the guidelines of the Macular Photocoagulation Study Group [32]. Retinal angiomatous proliferation (RAP) was classified as occult lesions. Review of the entire group of patients was also performed in a masked fashion (with respect to previous lesion type classifications and to genotypes) by one of the investigators (I.C.). There was agreement in 83.4% of cases between this investigator and the classification by the treating retina specialist (kappa measurement of agreement=0.68, p<0.0001). Classification of lesion type according to the observer who reviewed the entire group of patients was used for statistical analysis. The standard PDT protocol for NVAMD was applied [33]. Briefly, patients received 6 mg/m2 body surface area of verteporfin (Visudyne; Novartis Ophthalmics, Hettlingen, Switzerland) intravenously over 10 min. Fifteen min after commencement of the infusion exposure of 50 J/cm2 was applied at the radiant level of 600 mW/cm2 over 83 s using a diode laser (Visulas s 690, Zeiss, Switzerland), and the PDT laser lens (Volk, Mentor, OH).
###end p 24
###begin p 25
The association between smoking and the risk for having NVAMD, and its interaction with the 10q26 SNPs was analyzed. Individuals were considered as smokers if they were smoking at the time of the study or if they smoked in the past. Individuals who never smoked were considered as non-smokers.
###end p 25
###begin title 26
Quantitative real-time RT-PCR
###end title 26
###begin p 27
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 221 222 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 260 261 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 262 263 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 266 267 266 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 916 921 910 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 940 947 934 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 1044 1049 1038 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 48 60 <span type="species:ncbi:9606">participants</span>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
HTRA1 mRNA levels were measured in WBCs from 27 participants (22 NVAMD patients and 5 unaffected controls older than 60 years of age). WBCs were separated from whole blood using hypotonic lysis buffer containing 155 mM NH4Cl (Gadot, Or Akiva, Israel), 10 mM CH2O3.NH3 (Sigma-Aldrich, St. Louis, MO), and 0.1 mM EDTA (pH 7.4; J.T. Baker, Philipsberg, NJ). Next, 8 ml of buffer was added to 4 ml of blood, which was then stored on ice for 10 min and centrifuged at 2,000x g at 4 degreesC for 10 min. Supernatant was discarded and the sequence was repeated an additional time. The WBC pellet was resuspended in 1 ml of TRI Reagent (Sigma). RNA was then extracted followed by treatment with DNase (DNAfree; Ambion, Austin, TX), and cDNA was synthesized from 1 ug of total RNA using the Reverse iT 1st Strand Synthesis Kit (ABgene, Epsom, UK) and oligo dT primers. Quantitative real-time RT-PCR (QPCR) was performed with HTRA1 specific primers (Table 1) using the ABI Prism 7000 SDS instrument (Applied Biosystems, Foster City, CA). Measurements of GAPDH were used for normalization of expression levels across samples.
###end p 27
###begin title 28
Statistical analysis
###end title 28
###begin p 29
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 210 211 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 560 562 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 738 740 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
Statistical analysis and power calculations were performed using SPSS (SPSS, Chicago, IL) and Instat software (GraphPad, San Diego, CA) as we have previously described [30]. Briefly, logistic regression and chi2 tests were applied to assess odds ratios, confidence intervals, and significance. Linkage disequilibrium was assessed by D' calculation. Based on the number of individuals included in the analysis this study had 85% power for identification of an association between genotypes and lesion type in the magnitude described by Brantley and colleagues [22]. The study also had 94% power for identification of an association between genotypes and visual acuity following PDT in the magnitude, which was described by the same group [25].
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
Association of 10q26 SNPs with NVAMD
###end title 31
###begin p 32
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 27 42 27 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 345 352 345 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 357 364 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
Both the HTRA1 SNP and the LOC387715/ARMS2 SNP complied with Hardy-Weinberg equilibrium. Genotypes for both SNPs were in almost complete linkage disequilibrium, with D' values of 1.00 for NVAMD patients and 0.96 for controls. Distribution of the genotypes for both SNPs was significantly different between NVAMD patients and controls (p<0.0001; Table 2 and Table 3).
###end p 32
###begin title 33
###xml 13 28 13 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Frequency of LOC387715/ARMS2 () alleles and genotypes in NVAMD patients and unaffected controls.
###end title 33
###begin p 34
###xml 39 54 39 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
Comparison of the frequency (%) of the LOC387715/ARMS2 () variant between NVAMD patients and controls in the entire Israeli population and in the Ashkenazi, Sephardic, and Arab subpopulations. Increased prevalence of the T variant was associated with the disease in the entire population as well as in Ashkenazi, Sephardic, and Arab subpopulation. CI- confidence interval, OR- odds ratio. The asterisk indicates reliable genotyping for  was obtained from 249 of the 255 patients and for each of the 119 controls. The hash mark represents there were too few Arabs to obtain reliable ORs and CIs for analysis of genotypes in this sub population.
###end p 34
###begin title 35
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Frequency of HTRA1 () alleles and genotypes in NVAMD patients and unaffected controls
###end title 35
###begin p 36
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Comparison of the frequency (%) of the HTRA1 () variant between NVAMD patients and controls in the entire Israeli population and in the Ashkenazi, Sephardic, and Arab subpopulations. Increased prevalence of the A variant was associated with the disease in the entire population as well as in Ashkenazi, Sephardic, and Arab subpopulation. CI- confidence interval, OR- odds ratio. The hash mark represents there were too few Arabs to obtain reliable ORs and CIs for analysis of genotypes in this sub population.
###end p 36
###begin p 37
###xml 34 49 34 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 256 263 256 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 575 582 575 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
Homozygotes for the T allele of  (LOC387715/ARMS2) had an odds ratio (OR) of 8.6 with a 95% confidence interval (CI) of 3.5-20.8, while heterozygotes had an OR of 2.3 (95% CI of 1.4-3.7) for having NVAMD compared with homozygotes for the wild-type allele (Table 2). Combined, individuals either homozygous or heterozygous for the T allele had an OR of 3.2 (95% CI of 2-5; p<0.0001) compared with individuals homozygous for the G allele for having AMD. Analysis according to allele distribution showed similar findings to analysis according to genotypes for each of the SNPs (Table 2).
###end p 37
###begin p 38
###xml 197 204 197 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
Homozygotes for the A allele of  had an OR of 10.7 (95% CI of 3.2-35.7), while heterozygotes had an OR of 1.8 (95% CI of 1.1-3) for having NVAMD compared with homozygotes for the wild-type allele (Table 3). Combined, individuals either homozygous or heterozygous for the A allele had an OR of 2.5 (95% CI of 1.6-4; p<0.0001) compared with individuals homozygous for the G allele for having AMD.
###end p 38
###begin p 39
###xml 139 154 139 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 221 222 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 297 298 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 373 380 369 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 389 394 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 465 466 459 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 502 503 494 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 533 534 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 609 616 599 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
Subgroup analysis was performed to evaluate for association of both SNPs with NVAMD among Ashkenazi Jews, Sephardic Jews, and Arabs. The  (LOC387715/ARMS2) SNP was associated with NVAMD among Ashkenazi Jews (p<0.0001, chi2 test), Sephardic Jews (p=0.0003, chi-square test), and Arabs (p=0.036, chi2 test). Analysis according to allele distribution showed similar findings (Table 2). The  (HTRA1) SNP was also associated with NVAMD among Ashkenazi Jews (p=0.011, chi2 test), Sephardic Jews (p=0.044, chi2 test), and Arabs (p=0.05, chi2 test). Analysis according to allele distribution showed similar findings (Table 3).
###end p 39
###begin p 40
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
Smoking is an established risk factor for AMD. Since this risk factor was also associated with chromosome 10q26 SNPs in other populations [11], we evaluated its effect in our population. Smoking was associated with the risk for having AMD (OR of 3; 95% CI of 1.7-5.3; p<0.001) in the entire population; however, logistic regression found no interactions between smoking and either homozygosity (p=0.359) or heterozygosity for the risk allele of . There were also no interactions between smoking and either homozygosity (p=0.99) or heterozygosity (p=0.29) for the risk allele of .
###end p 40
###begin title 41
Association of 10q26 SNPs with phenotype of NVAMD
###end title 41
###begin p 42
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 71 86 71 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
###xml 506 518 <span type="species:ncbi:9606">participants</span>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
Following the establishment of an association among the HTRA1 SNP, the LOC387715/ARMS2 SNP, and NVAMD in the Israeli population, we explored possible correlations between the genotypes and clinical characteristics of NVAMD and response to PDT. This analysis included 143 sequential NVAMD patients who were treated in the Department of Ophthalmology of the Hadassah Medical Center and who were characterized in terms of phenotype and response to PDT. Reliable genotyping for  was obtained from all of these participants and for  from 139 of these patients.
###end p 42
###begin p 43
###xml 308 315 308 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 320 327 320 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 545 546 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1038 1045 1036 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 1050 1051 1048 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">5</xref>
There was no significant association between these SNPs and gender, history of smoking, lesion type, initial and final visual acuity, and number of PDT sessions required. The T allele of  was associated with a positive family history for AMD while the A allele of  showed a trend toward such an association (Table 4 and Table 5). While 23.7% of individuals carrying at least one risk allele (A) of  had a positive family history for AMD, only 8.6% of the individuals homozygous to the wild-type allele had a positive family history (p=0.043, chi2 test). However, this p value would lose significance if any form of multiple hypothesis testing correction was applied. Similarly, while 22.8% of individuals carrying at least one risk allele (T) of  had positive family history for AMD, only 4.4% of the individuals homozygous for the wild-type allele had a positive family history (p=0.008, chi square test). The risk alleles of both SNPs showed a trend toward an association with younger age of onset of NVAMD and with larger lesion size (Table 4 and 5).
###end p 43
###begin title 44
###xml 89 104 89 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
Correlation among demographic and phenotypic characteristics of NVAMD and genotyping for LOC387715/ARMS2 ().
###end title 44
###begin p 45
###xml 305 317 <span type="species:ncbi:9606">participants</span>
###xml 404 416 <span type="species:ncbi:9606">participants</span>
The asterisk indicates that classic lesions included predominantly classic and pure classic lesions. Occult lesions included minimally classic and occult lesions. Analysis according to four lesion types showed similar results. # Reliable information on family history was obtained from 117 out of the 143 participants included in this analysis, and smoking history was obtained from 138 of the 143 study participants.
###end p 45
###begin title 46
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Correlation among demographic and phenotypic characteristics of NVAMD and genotyping for HTRA1 ()
###end title 46
###begin p 47
###xml 300 312 <span type="species:ncbi:9606">participants</span>
###xml 399 411 <span type="species:ncbi:9606">participants</span>
The asterisk indicates classic lesions included predominantly classic and pure classic lesions. Occult lesions included minimally classic and occult lesions. Analysis according to four lesion types showed similar results. # Reliable information on family history was obtained from 117 out of the 143 participants included in this analysis, and smoking history was obtained from 138 of the 143 study participants.
###end p 47
###begin title 48
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
mRNA levels of HTRA1 in WBCs from NVAMD patients
###end title 48
###begin p 49
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 281 290 281 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1A</xref>
###xml 328 337 328 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1B</xref>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
mRNA levels of HTRA1 were measured using QPCR in WBCs from 22 NVAMD patients and 5 unaffected controls to assess the effect of the HTRA1 promoter variant on HTRA1 expression. ANOVA showed no significant differences in HTRA1 mRNA levels among individuals with different  genotypes (Figure 1A), and between patients and controls (Figure 1B). HTRA1 expression levels were similar in homozygote of the A allele and homozygote of the G allele (p=0.2).
###end p 49
###begin p 50
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 79 81 79 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A:</bold>
###xml 414 416 414 416 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</bold>
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 515 516 515 516 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 521 522 521 522 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 228 240 <span type="species:ncbi:9606">participants</span>
###xml 303 315 <span type="species:ncbi:9606">participants</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
Relative expression levels of HTRA1 in NVAMD patients and unaffected controls. A: Shown are expression levels in white blood cells according to rs11200638 genotypes in individuals homozygous for the wild-type allele (GG, n=13), participants homozygous for the risk allele (AA, n=6), and in heterozygous participants (AG, n=8). Differences between the three groups were not significant (p>0.1 for each comparison). B: Shown are mRNA levels of HTRA1 in 22 NVAMD patients and 5 unaffected individuals (p=0.9). In both A and B, RQ represents relative HTRA1 mRNA levels. Error bars represent standard deviation (SD).
###end p 50
###begin title 51
Discussion
###end title 51
###begin p 52
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 183 198 183 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 628 629 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 630 631 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 632 633 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
This study established an association between the A allele of , located in the putative promoter region of HTRA1, and the T allele of  (A69S variant), located in the coding region of LOC387715/ARMS2, and NVAMD in the Israeli population. Both SNPs are strongly associated with NVAMD among Ashkenazi and Sephardic Jews. While NVAMD is relatively uncommon among Arabs in Israel [34], our data suggest that 10q26 SNPs are also associated with NVAMD in this ethnic group. Similar to findings from fair-skinned populations and Japanese populations, these SNPs are in almost complete linkage disequilibrium in the Israeli populations [1,7,8].
###end p 52
###begin p 53
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 43 58 43 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 445 460 445 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 802 803 802 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 804 805 804 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 944 949 944 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 954 969 954 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
###xml 559 571 <span type="species:ncbi:9606">participants</span>
###xml 841 849 <span type="species:ncbi:9606">patients</span>
Increased prevalence of the same HTRA1 and LOC387715/ARMS2 variants among AMD patients was described in several fair-skinned populations as well as in cohorts from India, Japan, and China [1-8,21,35-39]. The magnitude of the association between these SNPs and NVAMD in Israel is similar to the one which was reported in other populations. For example, Rivera and colleagues [13] found an OR of 2.7 for AMD patients who were heterozygous for the LOC387715/ARMS2 A69S variant and an OR of 8.2 for patients who were homozygous for it . In the Israeli population participants who were heterozygous for this variant had an OR of 2.3 while those homozygous for it had an OR of 8.6 for having AMD. A stronger linkage of these SNPs with neovascular AMD compared with dry AMD was suggested by previous studies [2,9,40]. As our study focused on NVAMD patients, we were not able to evaluate for differences in the magnitude of the association between the HTRA1 and LOC387715/ARMS2 variants and the dry and neovascular forms of AMD.
###end p 53
###begin p 54
###xml 147 162 147 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 410 415 410 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 420 435 420 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 538 553 538 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 723 728 723 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 733 748 733 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 848 853 848 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 929 931 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
This study also evaluated if variable phenotype and response to therapy among NVAMD patients may be attributable to the chromosome 10q26 SNPs. The LOC387715/ARMS2 A69S variant was associated with younger age of examination for AMD, but not with other phenotypic characteristics of NVAMD in a recent study [40]. In accordance with that, a trend toward younger age of onset of NVAMD was associated with both the HTRA1 and LOC387715/ARMS2 variants in our study. Another observation suggesting an aggressive phenotype in association with the LOC387715/ARMS2 variant was reported by Brantley and colleagues [10] who proposed that this variant is associated with larger neovascular lesions. A trend toward an association of both HTRA1 and LOC387715/ARMS2 variants with larger neovascular lesions was also observed in this study. While association of the HTRA1 variant with the classic lesion type was described in a French population [26], such association was not identified in another fair-skinned population which was evaluated [10] or in the Israeli population.
###end p 54
###begin p 55
###xml 59 74 59 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 416 431 416 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 471 476 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 506 514 <span type="species:ncbi:9606">patients</span>
Brantley and coworkers did not find an association between LOC387715/ARMS2 A69S variant and response to bevacizumab injections in 86 patients. The same group did not find an association between this variant and response to PDT in 69 patients [10,25]. Yet, these authors found an association between response to bevacizumab injections and the CFH Y402H polymorphism. We confirmed this observation with respect to the LOC387715/ARMS2 variant and expanded it to include the HTRA1 variant in 143 Israeli NVAMD patients. Both variants were not associated with the visual outcome or with the number of PDT sessions required. Combined, these data do not support the existence of a major pharmacogenetic interactions among chromosome 10q26 SNPs and current therapies for NVAMD.
###end p 55
###begin p 56
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 48 63 48 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 189 194 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 289 304 289 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
It is still unclear if the HTRA1 variant or the LOC387715/ARMS2 variant has a causative role in the pathogenesis of AMD. While Dewan and Young and their colleagues [7,8] suggested that the HTRA1 variant is more strongly associated with the disease, Kanda and colleagues [6] suggested that LOC387715/ARMS2 rather than the HTRA1 variants explain the association of the chromosome 10q26 region with the disease. Since the variants in these genes are in almost complete linkage disequilibrium in each of the populations reported so far, additional functional studies are required to determine which variant is involved in the pathogenesis of the disease.
###end p 56
###begin p 57
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 629 634 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 659 664 659 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 774 779 774 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 792 797 792 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 923 928 923 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
In that respect, conflicting evidence has been reported regarding the functional significance of the HTRA1 promoter variant. Yang and colleagues [7] observed that this variant is associated with increased expression levels of the HTRA1 gene in 3 AMD patients homozygous to G allele of the HTRA1 promoter variant compared with 3 control patients homozygous to the A wild-type allele. Dewan and colleagues [8] described increased HTRA1 expression associated with the promoter variant. These authors speculated that altered HTRA1 expression levels might be involved in AMD. However, Kanda and colleagues [6] suggested that the same HTRA1 variant does not affect HTRA1 expression levels in cell lines or in the retina. We have also failed to identify an association between the HTRA1 variant and HTRA1 mRNA levels in WBCs. Yet, this data does not preclude an effect of the same promoter variant on retinal expression levels of HTRA1 in the context of AMD.
###end p 57
###begin p 58
It is still unclear which of the chromosome 10q26 variants is involved in the pathogenesis of AMD. However, our data show that additional genetic and environmental factors which underlie variable phenotype and response to therapy in NVAMD are yet to be identified.
###end p 58
###begin title 59
Acknowlegments
###end title 59
###begin p 60
We thank the individuals who provided blood samples for the purpose of the study. This study was supported in part by a grant from the Israel Science Fund (624/05).
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
HTRA1 promoter polymorphism predisposes Japanese to age-related macular degeneration.
###end article-title 62
###begin article-title 63
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Association of the HTRA1 gene variant with age-related macular degeneration in the Japanese population.
###end article-title 63
###begin article-title 64
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
HTRA1 variant increases risk to neovascular age- related macular degeneration in Chinese population.
###end article-title 64
###begin article-title 65
###xml 9 24 9 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
PLEKHA1- LOC387715/ARMS2-HTRA1 polymorphisms and exudative age-related macular degeneration in the French population.
###end article-title 65
###begin article-title 66
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
LOC387715/ARMS2/HTRA1 variants in polypoidal choroidal vasculopathy and age-related macular degeneration in a Japanese population.
###end article-title 66
###begin article-title 67
###xml 35 50 35 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/ARMS2</italic>
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration.
###end article-title 67
###begin article-title 68
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.
###end article-title 68
###begin article-title 69
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
HTRA1 promoter polymorphism in wet age-related macular degeneration.
###end article-title 69
###begin article-title 70
Association of CFH Y402H and LOC387715 A69S with progression of age- related macular degeneration.
###end article-title 70
###begin article-title 71
Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab.
###end article-title 71
###begin article-title 72
Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration.
###end article-title 72
###begin article-title 73
CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses.
###end article-title 73
###begin article-title 74
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.
###end article-title 74
###begin article-title 75
HTRA1 variants in exudative age-related macular degeneration and interactions with smoking and CFH.
###end article-title 75
###begin article-title 76
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Further mapping of 10q26 supports strong association of HTRA1 polymorphisms with age-related macular degeneration.
###end article-title 76
###begin article-title 77
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Association of HTRA1 polymorphism and bilaterality in advanced age-related macular degeneration.
###end article-title 77
###begin article-title 78
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking.
###end article-title 78
###begin article-title 79
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 112 116 <span type="species:ncbi:162683">mayo</span>
LOC387715/HTRA1 and complement factor H variants in patients with age- related macular degeneration seen at the mayo clinic.
###end article-title 79
###begin article-title 80
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human HTRA1 in the archived eyes with age- related macular degeneration.
###end article-title 80
###begin article-title 81
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
HTRA1: a novel regulator of physiological and pathological matrix mineralization?
###end article-title 81
###begin article-title 82
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA.
###end article-title 82
###begin article-title 83
Clinical Phenotypes Associated with the Complement Factor H Y402H Variant in Age-related Macular Degeneration.
###end article-title 83
###begin article-title 84
###xml 45 53 <span type="species:ncbi:9606">patients</span>
An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment.
###end article-title 84
###begin article-title 85
Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age- related macular degeneration.
###end article-title 85
###begin article-title 86
Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy.
###end article-title 86
###begin article-title 87
Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes.
###end article-title 87
###begin article-title 88
Complement factor H Y402H polymorphism and characteristics of exudative age-related macular degeneration lesions.
###end article-title 88
###begin article-title 89
The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration.
###end article-title 89
###begin article-title 90
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
###end article-title 90
###begin article-title 91
Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel.
###end article-title 91
###begin article-title 92
The Y chromosome pool of Jews as part of the genetic landscape of the Middle East.
###end article-title 92
###begin article-title 93
Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the macular photocoagulation study.
###end article-title 93
###begin article-title 94
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two- year results of 2 randomized clinical trials-tap report 2.
###end article-title 94
###begin article-title 95
Ethnic background as a risk factor for advanced age- related macular degeneration in Israel.
###end article-title 95
###begin article-title 96
HTRA1 variant confers similar risks to geographic atrophy and neovascular age-related macular degeneration.
###end article-title 96
###begin article-title 97
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Association of the HTRA1 - 625G>A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population.
###end article-title 97
###begin article-title 98
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
HTRA1 polymorphism in dry and wet age- related macular degeneration.
###end article-title 98
###begin article-title 99
Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration.
###end article-title 99
###begin article-title 100
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 140 148 <span type="species:ncbi:9606">Patients</span>
Variants in the 10q26 Gene Cluster (LOC387715 and HTRA1) Exhibit Enhanced Risk of Age-Related Macular Degeneration along with CFH in Indian Patients.
###end article-title 100
###begin article-title 101
###xml 22 30 <span type="species:ncbi:9606">Patients</span>
Phenotype Analysis of Patients With the Risk Variant LOC387715 (A69S) in Age-related Macular Degeneration.
###end article-title 101

